These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15763053)

  • 21. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study.
    Sainamthip P; Kongphanich C; Prasongsook N; Chirapongsathorn S
    World J Clin Cases; 2021 Oct; 9(30):9059-9069. PubMed ID: 34786388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
    Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
    Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer].
    Liu MZ; Wang XS; Cai L; Gu MF; Liu H; Li Q; Cui NJ; Zhang YQ; Li GH; Li JQ
    Ai Zheng; 2005 Jan; 24(1):82-6. PubMed ID: 15642207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.
    Kong WD; Cao JM; Xu J; Chen B; Yang T; Xu TT; Lu GM; Li J; Huang XE
    Asian Pac J Cancer Prev; 2012; 13(9):4757-61. PubMed ID: 23167415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
    Zuo CH; Xia M; Liu JS; Qiu XX; Lei X; Xu RC; Liu HC; Li JL; Li YG; Li QL; Xiao H; Hong Y; Wang XH; Zhu HZ; Wu QF; Burns M; Liu C
    Asian Pac J Cancer Prev; 2015; 16(1):245-51. PubMed ID: 25640360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience].
    Lin JJ; Wu W; Jiang XF; Jin XJ; Lu LJ; Bao LW
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):144-7. PubMed ID: 23714672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
    Italian Group for Antiemetic Research
    N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexamethasone prevents TACE-induced adverse events: A meta-analysis.
    Chang L; Wang W; Jiang N; Rao F; Gong C; Wu P; Yang J; Liu Z; Guo T
    Medicine (Baltimore); 2020 Nov; 99(47):e23191. PubMed ID: 33217828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Lin CI; Lin ZY; Hsieh MY; Huang CF; Chen SH; Chuang WL
    Kaohsiung J Med Sci; 2011 Dec; 27(12):554-9. PubMed ID: 22208538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
    Liang SN; Liu LL; Su HY; Feng B; Zhao GS; Xu K
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):790-2. PubMed ID: 19173817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
    Li H; Hu Y; Li N; Zhou Y
    Asian Pac J Cancer Prev; 2012; 13(4):1589-93. PubMed ID: 22799372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
    Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
    Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma].
    Wu JX; Huang JF; Yu ZJ; Meng XY; Li DG; Lu HM
    Ai Zheng; 2002 Aug; 21(8):881-4. PubMed ID: 12478898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.